180 related articles for article (PubMed ID: 12038300)
21. Species-specific CD1-restricted innate immunity for the development of HIV vaccine.
Takahashi H
Vaccine; 2010 May; 28 Suppl 2():B3-7. PubMed ID: 20510740
[TBL] [Abstract][Full Text] [Related]
22. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
23. [Vaccines against HIV].
Holm-Hansen C
Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
[TBL] [Abstract][Full Text] [Related]
24. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
26. Rebuilding the immune system: promising new therapy uses the HIV virus itself to awaken the damaged immune system. Interview by Brian Coppedge and Dan Dawson.
Moss R
STEP Perspect; 1998; 98(2):13-6. PubMed ID: 11365540
[TBL] [Abstract][Full Text] [Related]
27. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection.
Vieillard V; Costagliola D; Simon A; Debré P;
AIDS; 2006 Sep; 20(14):1795-804. PubMed ID: 16954720
[TBL] [Abstract][Full Text] [Related]
28. Improving HIV-specific immune responses in HIV-infected patients.
Hardy GA; Imami N; Gotch FM
J HIV Ther; 2002 May; 7(2):40-5. PubMed ID: 12553687
[TBL] [Abstract][Full Text] [Related]
29. Why vaccines are not the answer - the failure of V520 and the importance of cell-mediated immunity in the fight against HIV.
White A
Med Hypotheses; 2008 Dec; 71(6):909-13. PubMed ID: 18768264
[TBL] [Abstract][Full Text] [Related]
30. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
31. Rebuilding the immune system.
Averitt D
WORLD; 1999 Apr; (No 96):1-2. PubMed ID: 11366944
[TBL] [Abstract][Full Text] [Related]
32. The value of preserving HIV-specific immune responses.
Kaufmann DE; Rosenberg ES
J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711
[TBL] [Abstract][Full Text] [Related]
33. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
34. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
35. A safe, effective and affordable HIV vaccine--an urgent global need.
Joseph J; Etcheverry F; Alcami J; María GJ
AIDS Rev; 2005; 7(3):131-8. PubMed ID: 16302460
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
[TBL] [Abstract][Full Text] [Related]
37. AIDS vaccine development: the long and winding road.
Garber DA; Feinberg MB
AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
[TBL] [Abstract][Full Text] [Related]
38. Progress and obstacles in the development of an AIDS vaccine.
Letvin NL
Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
[TBL] [Abstract][Full Text] [Related]
39. Understanding the mechanisms and limitations of immune control of HIV.
Davenport MP; Ribeiro RM; Zhang L; Wilson DP; Perelson AS
Immunol Rev; 2007 Apr; 216():164-75. PubMed ID: 17367342
[TBL] [Abstract][Full Text] [Related]
40. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M
J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
